Pfizer's Q2 FY24-25 Financial Report Shows Mixed Results, MarketsMOJO Recommends Hold

Pfizer, a leading pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Pfizer's performance in Q2 FY24-25 has remained flat, with a score of 1 compared to 2 in the previous quarter. However, there are some positive aspects to the company's financials. The Profit After Tax (PAT) for the half-yearly period has shown a growth of 27.45% year on year, indicating a positive trend in the near term. The Net Sales for the quarter have also been the highest in the last five quarters, with a positive trend in the near term. The Profit Before Tax less Other Income (PBT) for the quarter has also been the highest in the last five quarters, with a positive trend in the near term. Additionally, the company's Cash and Cash Equivalents for the half-yearly period have been the highest in the last six periods, indicating an improvement in short-term liquidity.

However, there are also some areas of concern for Pfizer. The Operating Cash Flow for the year has been the lowest in the last three years, with a decline each year. This indicates a decrease in the company's cash revenues from business operations. The Debtors Turnover Ratio for the half-yearly period has also been the lowest in the last five periods, indicating a slower pace in settling the company's debtors. Furthermore, the Dividend per Share (DPS) for the year has been the lowest in the last five years, indicating a decrease in the company's distribution of dividends compared to previous years.

Overall, Pfizer's financial performance for the quarter ending September 2024 has been mixed, with some positive and negative aspects. Investors are advised to hold their positions in the company's stock, as suggested by MarketsMOJO.